Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous mesenchymal stem cells (Imperial College London)
- Development stage
- Unknown
- Lead developer
- Imperial College London
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
The autologous mesenchymal stem cell product is a cell-based biologic therapy developed by Imperial College London for the treatment of rapidly evolving active multiple sclerosis (MS). The product consists of mesenchymal stem cells (MSCs) harvested from the patient's own bone marrow, which are then expanded ex vivo and re-administered. These cells are thought to exert therapeutic effects through immunomodulation, neuroprotection, and the promotion of endogenous repair mechanisms such as remyelination. The therapy has been investigated in the Phase 2 STREAMS (Stem Cells in Rapidly Evolving Active Multiple Sclerosis) trial, which contributed to the larger international MESEMS (MEsenchymal StEm cells for Multiple Sclerosis) consortium study.
- Other names
- autologous mesenchymal stem cell productautologous MSC productautologous MSCsbone marrow-derived autologous mesenchymal stem cells
Beyond the preview
Go deeper on autologous mesenchymal stem cells (Imperial College London).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous mesenchymal stem cells (Imperial College London).